ダゾプリド

ダゾプリド
IUPAC命名法による物質名
	IUPAC名 4-amino-5-chloro-N-(1,2-diethylpyrazolidin-4-yl)-2-methoxy-benzamide;
臨床データ
法的規制	Uncontrolled;
投与経路	Oral
識別
CAS番号;	70181-03-2
ATCコード	none
PubChem	CID: 54801
ChemSpider	49487
UNII	CV07VSP2G8
化学的データ
化学式	C15H23ClN4O2
分子量	326.82 g/mol
	テンプレートを表示

ダゾプリド(Dazopride)は、ベンズアミド系の制吐薬、消化管機能改善薬である。未だ市販されたことはない^[1]^[2]^[3]^[4]^[5]。5-HT3受容体のアンタゴニスト及び5-HT4受容体のアゴニストとして作用する^[3]^[4]^[6]。胃腸への作用に加え、マウスでは、学習や記憶を手助けする効果が見られた^[7]。

出典[編集]

^ Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). “Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy”. Cancer Chemotherapy and Pharmacology 31 (6): 442–4. doi:10.1007/bf00685032. PMID 8453682.
^ Alphin RS, Proakis AG, Leonard CA, et al. (May 1986). “Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility”. Digestive Diseases and Sciences 31 (5): 524–9. doi:10.1007/bf01320319. PMID 3698769.
^ ^a ^b Costall B, Domeney AM, Gunning SJ, et al. (July 1987). “The action of dazopride to enhance gastric emptying and block emesis”. Neuropharmacology 26 (7A): 669–77. doi:10.1016/0028-3908(87)90227-9. PMID 3114664.
^ ^a ^b Costall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). “Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs”. Neuropharmacology 26 (9): 1321–6. doi:10.1016/0028-3908(87)90094-3. PMID 2890117.
^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9
^ Villalón CM, den Boer MO, Heiligers JP, Saxena PR (January 1991). “Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig”. British Journal of Pharmacology 102 (1): 107–12. doi:10.1111/j.1476-5381.1991.tb12140.x. PMC 1917868. PMID 2043916.
^ Montgomery, S. A.; Halbreich, Uriel (2000). Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press. ISBN 0-88048-885-9

[pmid8453682-1] Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). “Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy”. Cancer Chemotherapy and Pharmacology 31 (6): 442–4. doi:10.1007/bf00685032. PMID 8453682.

[pmid3698769-2] Alphin RS, Proakis AG, Leonard CA, et al. (May 1986). “Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility”. Digestive Diseases and Sciences 31 (5): 524–9. doi:10.1007/bf01320319. PMID 3698769.

[pmid3114664-3] Costall B, Domeney AM, Gunning SJ, et al. (July 1987). “The action of dazopride to enhance gastric emptying and block emesis”. Neuropharmacology 26 (7A): 669–77. doi:10.1016/0028-3908(87)90227-9. PMID 3114664.

[pmid2890117-4] Costall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). “Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs”. Neuropharmacology 26 (9): 1321–6. doi:10.1016/0028-3908(87)90094-3. PMID 2890117.

[isbn0-412-46630-9-5] David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9

[pmid2043916-6] Villalón CM, den Boer MO, Heiligers JP, Saxena PR (January 1991). “Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig”. British Journal of Pharmacology 102 (1): 107–12. doi:10.1111/j.1476-5381.1991.tb12140.x. PMC 1917868. PMID 2043916.

[isbn0-88048-885-9-7] Montgomery, S. A.; Halbreich, Uriel (2000). Pharmacotherapy for mood, anxiety, and cognitive disorders. Washington, DC: American Psychiatric Press. ISBN 0-88048-885-9

[1]

[2]

[3]

[4]

[5]

[6]

[7]